InMode Ltd INMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INMD is a good fit for your portfolio.
News
-
Thinking about trading options or stock in Alibaba Group, Arista Networks, SentinelOne, Asana, or Inmode?
-
InMode's stock slides 13% after Israeli medtech company issues profit warning
-
InMode Revises Full-Year 2023 Guidance
-
InMode to Present at Upcoming Investor Conferences and Events
-
InMode Reports Third Quarter 2023 Financial Results; Quarterly Revenue of $123.1M Represents 2% Year-Over-Year Growth
-
InMode Files Patent Infringement Complaint Against BTL Industries, Inc. (d/b/a BTL Aesthetics)
-
InMode Expects Third Quarter 2023 Revenue Between $122.8M-$123.0M, Lowering Full-Year 2023 Revenue Guidance to $500M-$510M vs. Original Estimates of $530M-$540M
-
InMode Affirms Safety of Management, Employees and Production Sites
Trading Information
- Previous Close Price
- $20.74
- Day Range
- $20.92–21.75
- 52-Week Range
- $18.58–48.24
- Bid/Ask
- $21.69 / $21.71
- Market Cap
- $1.80 Bil
- Volume/Avg
- 1.2 Mil / 2.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- 8.01
- Price/Sales
- 3.57
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its products platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 480
- Website
- https://www.inmodemd.com
Valuation
|
Metric
|
INMD
|
|---|---|
Price/Earnings (Normalized) | 8.01 |
Price/Book Value | 2.39 |
Price/Sales | 3.57 |
Price/Cash Flow | 8.91 |
Price/Earnings
INMD
Financial Strength
|
Metric
|
INMD
|
|---|---|
Quick Ratio | 11.87 |
Current Ratio | 12.51 |
Interest Coverage | — |
Quick Ratio
INMD
Profitability
|
Metric
|
INMD
|
|---|---|
Return on Assets (Normalized) | 33.09% |
Return on Equity (Normalized) | 37.05% |
Return on Invested Capital (Normalized) | 34.60% |
Return on Assets
INMD
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
ABT
| Abbott Laboratories | Fhftd | $180.6 Bil | |
SYK
| Stryker Corp | Knsw | $109.9 Bil | |
MDT
| Medtronic PLC | Vhm | $105.8 Bil | |
BSX
| Boston Scientific Corp | Nkqsyd | $80.6 Bil | |
DXCM
| DexCom Inc | Pnbpx | $45.4 Bil | |
EW
| Edwards Lifesciences Corp | Pvwzgm | $41.4 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Xms | $24.5 Bil | |
PHG
| Koninklijke Philips NV ADR | Xzvzsr | $18.1 Bil | |
ALGN
| Align Technology Inc | Pssxbhj | $16.6 Bil | |
PODD
| Insulet Corp | Wbbrt | $13.6 Bil |